Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLC

Next Previous
X
Search
Trial Profile

Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLC

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Dexamethasone; Dexamethasone; Etoposide; Etoposide; Folic acid; Hydroxocobalamin; Pemetrexed
  • Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INCREASE

    • Most Recent Events

    • 24 Oct 2023 Results assessing the immune-modulating effects of neoadjuvant immunotherapy and CRT on TDLN in T3-4N0-1 NSCLC patients, presented at the 48th European Society for Medical Oncology Congress.
    • 12 Sep 2023 Status changed to completed, according to results presented at the 24th World Conference on Lung Cancer.
    • 12 Sep 2023 Results assessing surgical outcomes in the complete study cohort in patients with (borderline) resectable NSCLC presented at the 24th World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top